Stockscreener 앱 받기
27.93
0.53%
-0.15
시간 외 거래:
27.93
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares By Investing.com - Investing.com India
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares - Investing.com
Aug Technicals: What drives Enliven Therapeutics Incs stock priceJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Aug Breakouts: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Macro Moves & Advanced Technical Analysis Signals - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year HighWhat's Next? - MarketBeat
Quarterly Trades: Is Enliven Therapeutics Inc a speculative investment2025 Support & Resistance & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Highlights: How sensitive is Enliven Therapeutics Inc to inflation2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - AOL.com
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Update Report: Can Enliven Therapeutics Inc disrupt its industryPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress - Sahm
Enliven Therapeutics Executive Sells 20,000 Shares - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Pioneer with 61% Potential Upside - DirectorsTalk Interviews
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aug Sectors: What is DATSs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Market Outlook: Is Enliven Therapeutics Inc attractive for institutional investorsStop Loss & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com - Investing.com South Africa
Day Trade: What hedge funds are buying TSLA2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Enliven Therapeutics director Heyman sells $32,901 in stock - Investing.com
Why (ELVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Comparing CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN) - Defense World
Stocks To Watch: Enliven Therapeutics Sees RS Rating Jump To 85 - Investor's Business Daily
Assessing Enliven Therapeutics (ELVN) Valuation After Positive Phase 1b ENABLE Trial Update - Sahm
Will Enliven Therapeutics Inc. stock see insider buyingChart Signals & Short-Term Swing Trade Alerts - bollywoodhelpline.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4%Should You Buy? - MarketBeat
Have Enliven Therapeutics Insiders Been Selling Stock? - Sahm
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. attractive for institutional investorsQuarterly Market Summary & High Return Trade Opportunity Guides - bollywoodhelpline.com
Moving Averages: Does Enliven Therapeutics Inc stock have upside surprise potential2025 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN - Investing.com Canada
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares of Stock - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8%Here's What Happened - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares - Investing.com India
Enliven Therapeutics Insider Sold Shares Worth $3,476,014, According to a Recent SEC Filing - marketscreener.com
Stocks with rising relative price strength: Enliven Therapeutics - MSN
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s Why - Defense World
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data - Sahm
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - FinancialContent
Enliven Therapeutics (NASDAQ:ELVN) Trading 21.1% HigherTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com - Investing.com India
Enliven Therapeutics stock hits 52-week high at $25.64 - Investing.com
0.36%
1.16%
자본화:
|
볼륨(24시간):